Denali Therapeutics (DNLI) Tax Provisions (2019 - 2023)
Denali Therapeutics (DNLI) posted quarterly Tax Provisions of $30000.0 for Q4 2023, up 600.0% year-over-year from $4285.7 in Q4 2022, and up 600.0% quarter-over-quarter from -$6000.0 in Q4 2022.
Denali Therapeutics (DNLI) Tax Provisions (2019 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has reported Tax Provisions for 5 consecutive years, with $30000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Tax Provisions rose 600.0% year-over-year to $30000.0; the TTM figure through Dec 2023 stood at $24000.0 (up 104.33% YoY), while the FY2025 annual figure was $102000.0, up 50.0% from the prior year.
- Tax Provisions grew to $30000.0 in Q4 2023 per DNLI's latest filing, from -$6000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $823000.0 in Q4 2020 and bottomed at -$575000.0 in Q4 2021.
- Historically, Tax Provisions has averaged -$37900.0 across 5 years, with a median of $10500.0 in 2022.
- Annual changes were most pronounced in 2021 — Tax Provisions plunged 169.87% — and 2023, when it jumped 600.0%.
- Denali Therapeutics' Tax Provisions stood at -$400000.0 in 2019, then surged by 305.75% to $823000.0 in 2020, then slumped by 169.87% to -$575000.0 in 2021, then soared by 98.96% to -$6000.0 in 2022, then surged by 600.0% to $30000.0 in 2023.
- Business Quant data shows DNLI's Tax Provisions at $30000.0 in Q4 2023, -$6000.0 in Q4 2022, and $27000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2022 | -6,000.00 |
| Jun 30, 2022 | 27,000.00 |
| Dec 31, 2021 | -575,000.00 |
| Dec 31, 2020 | 823,000.00 |
| Sep 30, 2020 | 56,000.00 |
| Jun 30, 2020 | 79,000.00 |
| Mar 31, 2020 | -100,000.00 |
| Sep 30, 2019 | -400,000.00 |
| Jun 30, 2019 | -313,000.00 |